Canaccord Genuity analyst Whitney Ijem has maintained their bullish stance on RARE stock, giving a Buy rating today.
Whitney Ijem has given his Buy rating due to a combination of factors influencing Ultragenyx Pharmaceutical’s outlook. The company’s recent earnings report showed consistent global demand for its commercial products, and all pipeline programs are progressing as planned. Despite a minor revenue shortfall this quarter, the company maintained its full-year guidance, indicating confidence in its future performance.
Moreover, the focus on setrusumab for osteogenesis imperfecta is promising, with management optimistic about meeting key interim analysis endpoints. The upcoming PDUFA date for UX111 in MPS IIIA is on schedule, with supportive clinical and biomarker data backing its anticipated approval. Additionally, the company is not significantly affected by tariffs and continues to explore various scenarios to mitigate any potential impacts. These factors collectively support the Buy rating recommendation.
In another report released today, Citi also maintained a Buy rating on the stock with a $110.00 price target.
RARE’s price has also changed moderately for the past six months – from $50.520 to $35.060, which is a -30.60% drop .